Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756924 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
A Phase 2 study, sponsored by Arrevus.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01756924: Clinical Trial Phase 2 study, sponsored by Arrevus.
NCT01756924 is a Phase 2 study that was terminated before completion, run by Arrevus. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01756924, a Phase 2 study, was terminated before completion, sponsored by Arrevus.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections
Primary Outcome
Clinical success is defined as the absence of persistent infection in a patient who did not receive alternative antibiotic therapy targeting the infection.
Interventions
- DRUG Rifampin
- DRUG CEM-102
- DRUG IV or Oral standard of care antibiotics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Why NCT01756924 stopped before completion
NCT01756924 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT01756924 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01756924 about?
NCT01756924 is a clinical study titled "Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection". To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections
What is the current status of trial NCT01756924?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2012-12. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01756924?
The interventions under investigation include: Rifampin (DRUG), CEM-102 (DRUG), IV or Oral standard of care antibiotics (DRUG).
Who is sponsoring clinical trial NCT01756924?
This trial is sponsored by Arrevus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01756924's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia